Longevity medicine treats upstream of disease. Here's how clinicians can lead the shift with evidence, not hype.
Longevity medicine is treating upstream of the diseases we were trained to treat. Not after the diagnosis is made. Not once function has already declined. That is the single most important takeaway from my talk at the Creative Careers in Medicine Conference 2026, and it is the idea that should reshape how we think about prevention.
Our patients are already there. They are talking about risk, prevention and intervention, and they are doing it with people who are not us. The question is not whether healthcare moves upstream. It already has. The question is whether we, as clinicians, lead that transition, or inherit a version of it shaped by everyone else who is not clinical.
The Gap Between Hype and Science
Where are our patients right now? Standing in the gap between mainstream medicine and an unregulated online marketplace.
On the mainstream side, they see us. Annual health check, bloods unremarkable, they do not meet disease criteria, and we say, "You're fine, see you next year." That is a missed opportunity to address risk before it becomes disease.
On the other side is a market offering more certainty than the evidence allows. I do not say that negatively. The market has understood a real need and captured it. Patients want interpretation, context, and a plan to prevent disease before it happens. The problem is they are navigating an unregulated online marketplace without clinical oversight. Misinformation, testing, supplements, emerging therapies, all without us.
So the question is not whether this shift is happening. It is whether we will be present where our patients already are.
The Signal: People Are Spending on Prevention
A quick snapshot. The global wellness economy in 2024 was around 6.8 trillion US dollars, roughly four times global pharmaceutical sales combined, and it is forecast to hit almost 10 trillion by 2029. Do the maths. People are spending, and they are spending mostly outside healthcare.
Because they want prevention, they want interpretation, and they want agency. That demand is already shaping the environment around our patients. The opportunity now is to bring better judgement into it.
Innovation Without Ideology
If there is one idea I want you to remember, it is this: there are two ways we get emerging therapies wrong.
The first is mistaking mechanism for outcome. A receptor pathway can be elegant. The pre-clinical data can be interesting. The biology can be plausible. None of that demonstrates meaningful human outcomes. Plausibility is where the work starts, not where it ends.
The second is reading no large randomised controlled trial as a verdict. It is not permission to claim benefit, but it is not automatically the final answer either. Trials need money, time, and a commercial reason to fund them. For older or harder to commercialise molecules, the evidence can be thin for economic reasons as much as scientific ones.
So our task is not to be an advocate or a sceptic. It is to say clearly what we know, what we do not, what the risks are, and what governance is required. That is clinical judgement, and it applies to every claim in longevity medicine.
Start With What Remains Unglamorous
So what does that look like in longevity practice? I apply three filters to everything: a new scan, a supplement, an emerging therapy, a wearable, or whatever new thing is trending.
The evidence. Are there human outcomes? Early clinical signals? Or biological plausibility alone?
The safety profile. Dosing, duration, interactions, monitoring, follow up.
The upside. Would I recommend it to a friend if there was nothing in it for me? The answer should be fairly obvious.
But before any of that, the pillars of wellness: movement, strength, cardiorespiratory fitness, quality sleep, nutrition with whole foods not processed, and social connection. If you are not doing any of that, none of the rest of longevity medicine matters. It is pure theatre. Yes, it is unglamorous.
The question is not simply, “Do emerging therapies work?”
When I ask audiences how many have heard friends, colleagues, or the media discussing emerging therapies, most hands usually go up. When I then ask how many have prescribed one, the response is understandably more reserved and that is entirely okay.
The purpose of that question is not to shame anyone or make a judgement about individual clinical decisions. Rather, it highlights a practical reality: emerging therapies are already present in the clinical landscape, whether we choose to engage with them directly or not.
That is what makes them such a valuable case study. They are not synonymous with longevity medicine, nor is this intended to become a simplistic debate about whether they “work.” The more useful question is how we, as clinicians, assess therapies that generate interest before the evidence, regulation, and clinical consensus have fully caught up.
The more useful question is: what training do we have to assess this responsibly? Because your patient may ask whether you prescribe, or ask you to refer to a service that does, or they may be comfortable enough to disclose that they are already using one. And then what? Do you know what to monitor? What adverse effects to ask about? When to escalate?
The answer is a framework, not just compounds, doses or a stack. How to read the evidence. Assess safety. Understand the lawful environment. Name the uncertainty, with data or the lack of it. And arrange appropriate care for your patient.
That gap is why I wrote Foundations of Peptide Therapeutics, a course anchored to RACGP and NHMRC standards, reviewed by a professor of public health, with seven modules and seven hours of CPD. It names the science, and just as importantly, it names where the science runs out. Not to promote emerging therapies, not to demonise them. Education is the bridge between hype and science.
Judgement Is the Product
To finish, three points.
One. The opportunity is upstream of the diseases we were trained to treat. Our patients are already there. In many ways they got there before us.
Two. Our value is not more information. Our value is trusted interpretation. Someone who has read the evidence, can say what it does and does not show, and can apply judgement without hiding the uncertainty.
Three. The question is not whether healthcare moves upstream. It already has. The question is whether we, as clinicians, lead that transition, or inherit a version of it shaped by everybody else who is not clinical.
If you are a clinician wanting to build this capability, the starting point is a conversation. We discuss emerging therapies (clinical governance required) and how to assess them in consultation. Book a time to talk about what this could look like for your practice.
General information, not individual medical advice. Speak to your own doctor.
